Hypovolemia

Vivacelle Bio Integrates Sub-Saharan Africa Strategy into Series B Financing Round

Retrieved on: 
Thursday, February 22, 2024
Blood pressure, Blood, School, Sepsis, Woman, IIA, Bleeding, Doctor of Philosophy, Resuscitation, The, Shock, MD, Diarrhea, Temperature, Septic, University, Nitric oxide, Shock (mechanics), Senior advisor, Finger, Life, Urinary tract infection, Risk, Internal bleeding, Pelvic floor dysfunction, Malaria, Hypovolemia, Nanoparticle, Gangrene, Neonatal sepsis, JD, Patient, Septic shock, Clinical trial, UMKC, Child, Reperfusion injury, Hypotension, Partnership

Targeted $20M Series B Round to include Sub-Saharan Africa in product development.

Key Points: 
  • Targeted $20M Series B Round to include Sub-Saharan Africa in product development.
  • Vivacelle Bio is partnering with Propelevate to drive the Sub-Saharan Africa strategy, which is fully integrated into its Series B financing round.
  • Through partnership with Propelevate, Vivacelle Bio will engage global health funders and stakeholders during final stages of product development, and Propelevate will drive Vivacelle Bio's go-to-market strategy for African markets upon regulatory approval.
  • "We are excited to partner with Vivacelle Bio because of their commitment to Sub-Saharan Africa.

Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook

Retrieved on: 
Thursday, May 11, 2023
Research, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Neurology, FDA, Health, Diabetes, CD, Civil service commission, CER, Takeda, Hypovolemia, Hereditary angioedema, ADHD, PDT, Neuroscience, ADCETRIS, Multifocal motor neuropathy, Lung cancer, Ulcerative colitis, Lymphoma, Inflammatory bowel disease, HAE, Emerging market, Acquisition, UC, Investment, Patient, EGFR, Growth, PP, Primary immunodeficiency, Immunology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, European Commission, PP&E, Pharmaceutical industry, Hypoalbuminemia

Rare Diseases, with 723.4 billion yen in reported revenue, grew 4.8% on a CER basis.

Key Points: 
  • Rare Diseases, with 723.4 billion yen in reported revenue, grew 4.8% on a CER basis.
  • Plasma-Derived Therapies (PDT) Immunology, with 678.4 billion yen in reported revenue, delivered outstanding growth of 15.3% on a CER basis.
  • ALUNBRIG® (for non-small cell lung cancer) also grew 35% on a CER basis with strong demand in Europe, China, and Growth & Emerging Markets.
  • This approval marks the first approval of QDENGA in Latin America as Takeda continues to progress additional regulatory filings in other dengue-endemic countries.

What is sepsis? How to spot, manage and prevent it

Retrieved on: 
Sunday, April 23, 2023
Blood pressure, Infection, CT, Conversation, Central nervous system, Diabetes, Sepsis, HIV, Gallbladder, Hypotension, Public, Respiratory rate, Marie Cassidy, Osteomyelitis, Non-communicable disease, Pancreas, End organ damage, Respiratory system, National Institute, Organ dysfunction, Temperature, Risk, Diarrhea, History, Septic shock, Chronic obstructive pulmonary disease, Pyelonephritis, MRI, Magnetic resonance imaging, Vital signs, Patient, Sanitation, Blood, Water, Abscess, Viral, Hypovolemia, Abdomen, National Institute for Communicable Diseases, Conditional sentence, Confusion, Personality, Septic, Liver, Burns, Heart rate, Acute respiratory distress syndrome, Mortality, Society, ICU, System, Computerize, Meningitis, Pneumonia, Skin, Kidney disease, Disease, Pharmaceutical industry, Vaccine, Sewage treatment, Nursing, Medical device, Tachypnea

Sepsis, a life threatening condition, happens when the body has an excessive immune response to an infection in the blood stream.

Key Points: 
  • Sepsis, a life threatening condition, happens when the body has an excessive immune response to an infection in the blood stream.
  • The Conversation Africa’s Ina Skosana spoke to pathologists from the National Institute of Communicable Diseases about the illness and its impact.

What causes sepsis?

    • There are common causes of sepsis.
    • Infections of the central nervous system (meningitis) as well as skin and soft tissue (surgical site, wounds or burns) are also common causes of sepsis.

Who is at risk of sepsis?

    • But babies up to one month old and people older than 65 years have a higher risk of developing the condition.
    • Prolonged hospital stays or admission to an intensive care unit (ICU) can also increase the risk of sepsis.

What are the symptoms of sepsis and septic shock?


    Symptoms of sepsis are not specific. These may include one or more of these:
    Septic shock is a progression of sepsis. It’s characterised by hypotension (low blood pressure), hypovolaemia (loss of bodily fluids such as water and blood) and organ dysfunction. Patients typically present with extreme confusion or loss of consciousness.

How is sepsis and septic shock diagnosed?

    • There are various tests available to diagnose sepsis and septic shock.
    • Sepsis and septic shock are clinical syndromes defined by a combination of signs, symptoms, laboratory and physiological abnormalities.
    • A variety of clinical variables and tools such as vital signs (heart rate, respiratory rate, temperature and blood pressure), laboratory blood tests (confirmation of infection) and clinical examinations have to be reviewed for sepsis screening.

How is sepsis managed?

    • Patients with sepsis need close monitoring and treatment in a hospital ICU.
    • Intravenous fluids should be started as soon as possible, preferably within the first three hours of sepsis being identified.

How is sepsis prevented?

    • In healthcare facilities prevention of the sepsis include practising appropriate infection prevention and control measures which can reduce infections by 50%.
    • Recognising sepsis early and introducing antibiotics treatment early can reduce the likelihood of sepsis progressing to mortality.
    • Anyone who has signs and symptoms of sepsis, even when the underlying infection is not apparent, should seek medical care immediately.

Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Septic shock, OTA, Hypovolemia, Physician, United States Army Medical Research and Development Command, United States Army Medical Research Institute of Infectious Diseases, ECMO, Extracorporeal membrane oxygenation, Biomedical technology, Probability, Patient, Clinical trial, Shock, Inflammation, Food, Mortality, Nitric oxide, Shock (mechanics), Survival, Therapy, FDA, MTEC, NO, Food and Drug Administration, Bio, Blood pressure, Death, Kidney, Pharmaceutical industry

Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.

Key Points: 
  • Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.
  • Severe septic shock patients experience a drastic drop in blood pressure that is associated with multiple organ failure causing patient death.
  • While conventional fluids are effective for treating absolute hypovolemia, they are ineffective for treating relative hypovolemia, which is caused by excessive production of nitric oxide (NO) in septic shock.
  • In the VBI-S Phase IIa trial, reversal of relative hypovolemia led to an increase in blood pressure and improvement of organ function.

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

Retrieved on: 
Thursday, February 2, 2023
Research, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Neurology, FDA, Health, Diabetes, CER, Arrowhead Pharmaceuticals, Lupus, Major depressive disorder, Safety, Acquisition, ADHD, Fibrosis, Lung cancer, National Medical Products Administration, Multiple myeloma, Psoriasis, Neuroscience, Psoriatic arthritis, PDT, Biologics license application, PP&E, Lymphoma, YTD, Takeda, Growth, Fever Dream, OPTIC, NMPA, Hypovolemia, European Commission, AURORA, VEGFR, Investment, Inflammatory bowel disease, Cytomegalovirus, Civil service commission, Patient, Hereditary angioedema, Therapy, Liver disease, EC, Infection, U.S. FDA, CMV, Primary immunodeficiency, TYK2, ADAMTS13, Hand, Ulcerative colitis, SEQUOIA, Emerging market, Toll, Narcolepsy, USD, Disease, PP, Pharmaceutical industry, Leukemia, Hypoalbuminemia, F4, EU

Growth in our key business areas in FY2022 Q3 YTD was driven largely by Growth & Launch Products1, which delivered reported revenue of 1,199.6 billion yen, marking a +20% increase on a CER basis.

Key Points: 
  • Growth in our key business areas in FY2022 Q3 YTD was driven largely by Growth & Launch Products1, which delivered reported revenue of 1,199.6 billion yen, marking a +20% increase on a CER basis.
  • Sales of TAKHZYRO® (for hereditary angioedema) grew +25% on a CER basis due to expansion of the prophylactic market, continued geographic expansion and strong patient uptake.
  • Plasma-Derived Therapies (PDT) Immunology, with 502.4 billion yen in reported revenue, delivered outstanding growth of +18% on a CER basis.
  • Takeda has continued to deliver on its ability to bring new therapies to patients and capitalize on momentum within its innovative pipeline.

VirTech Bio presenting at the Florida Venture Summit Dec. 6, 2022

Retrieved on: 
Thursday, December 1, 2022
Multiplicity (chemistry), Science, Blood, HBOC, IND, MM, Hypovolemia, CGMP, Death, MD, Bleeding, Patent, Medicine, United States Department of Defense, Medical device, Pharmaceutical industry

Dr. Hack became CEO of VirTech Bio in March 2022.

Key Points: 
  • Dr. Hack became CEO of VirTech Bio in March 2022.
  • VirTech Bio has previously raised seed funding of $6.7 MM which leverages $13.7 MM awarded in non-dilutive funding to date, primarily from the DoD.
  • The Florida Venture Summit is being held in Miami (Dec. 6 -7, 2022) and is billed as a premier event 'Where Innovation Meets Capital'.
  • For more information about VirTech Bio contact us at: [email protected] .

Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis.

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Lung, Bio, Sepsis, Septic shock, Patient, Blood pressure, Mortality, Food and Drug Administration, Kidney, Food, Hypovolemia, Company, Doctor of Philosophy, End organ damage, CEO, Survival, Death, FDA, Pharmaceutical industry

Vivacelle Bio, Inc., a privately held company focused on the development of improved treatments for septic shock, today announced early results from its Phase IIa clinical trial of VBI-S in septic shock patients.

Key Points: 
  • Vivacelle Bio, Inc., a privately held company focused on the development of improved treatments for septic shock, today announced early results from its Phase IIa clinical trial of VBI-S in septic shock patients.
  • All patients in whom vasopressors were weaned, reached the secondary endpoint of the trial which is a reduction in the dose of vasopressors.
  • VBI-S was effective even in patients on very high doses of multiple vasopressors.
  • For more information on VBI-S or Vivacelle Bio, Inc., please contact Harven DeShield, J.D., Ph.D., CEO, at 716-830-8932 or via email, [email protected] .

Smiths Medical Issues Urgent Medical Device Correction Letter Notifying Customers of a Potential Issue with Level 1® H-2 Pressure Chambers used with Level 1 Fast Fluid Flow Fluid Warmers

Retrieved on: 
Wednesday, August 3, 2022
Pressure, Letter, Hypovolemia, Model, Hypotension, IV, Death, Risk, D-70, Hypothermia, Medical device

MINNEAPOLIS, Aug. 3, 2022 /PRNewswire/ --Smiths Medical issued an Urgent Medical Device Correction Letter to notify affected customers of a potential issue with specific Level 1H-2 Pressure Chambers used with the Level 1 Fast Flow Fluid Warmers.

Key Points: 
  • MINNEAPOLIS, Aug. 3, 2022 /PRNewswire/ --Smiths Medical issued an Urgent Medical Device Correction Letter to notify affected customers of a potential issue with specific Level 1H-2 Pressure Chambers used with the Level 1 Fast Flow Fluid Warmers.
  • In 2015, Smiths Medical implemented a design change to widen the hinge/latch assembly on the Level 1 H-2 Pressure Chambers used with the Level 1 Fast Flow Fluid Warmers (Models H-1025 or H-1200) or added it to the H-1000 model.
  • Affected product was distributed in the United States between December 19, 2016, and March 10, 2022.
  • However, all Level 1 H-2 Pressure Chamber devices have the potential to be affected by this issue, because some devices may have received a hinge/latch replacement during that timeframe.

The Worldwide Albumin Industry is Expected to Reach $8.9 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 20, 2022
Health, Pharmaceutical, People, Serum albumin, Antibody, Awareness, Degenerative disease, Fatality, Acute respiratory distress syndrome, Acute liver failure, Trauma, Health, Hypovolemia, Adoption, CAGR, Bleeding, Drug development, Chronic liver disease, Therapy, Growth, Shock, Burns, Prevalence, Albumin, Hypoalbuminemia

The "Albumin Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2021--2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Albumin Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2021--2030" report has been added to ResearchAndMarkets.com's offering.
  • The Albumin market was valued at $4,813.5 million in 2020, and is estimated to reach $8,956.07 million by 2030, growing at a CAGR of 6.4% from 2021 to 2030.
  • Albumin is obtained from plasma fractionation process where human serum albumin and bovine serum albumin is most widely used.
  • This has further encouraged many key players to enter emerging markets, thus offering a lucrative growth opportunity in the albumin market.

The Worldwide Postpartum Hemorrhage Devices Industry is Expected to Reach $1 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Medical Devices, Health, Consumer, Surgery, Women, Baby, Maternity, Smart contract, Bleeding, Lists of countries and territories, Maternal death, Postpartum bleeding, Internal bleeding, Gynaecology, PPH, Death, Childbirth, Oxytocin, Disease, Obstetrics, Mortality, Uterus, World, UBT, Hypovolemia, CAGR, Hysterectomy, World Health Organization, Tranexamic acid, Don't Underestimate My Love for You, American College, Uterine balloon tamponade, Method, WHO, Pet, Birth control

The Global Postpartum Hemorrhage (PPH) Devices Market size is expected to reach $1.05 billion by 2028, rising at a market growth of 5.2% CAGR during the forecast period.

Key Points: 
  • The Global Postpartum Hemorrhage (PPH) Devices Market size is expected to reach $1.05 billion by 2028, rising at a market growth of 5.2% CAGR during the forecast period.
  • Postpartum hemorrhage (PPH) is the most prevalent type of obstetric hemorrhage and one of the primary causes of maternal mortality.
  • The postpartum hemorrhage devices market is growing due to a rise in complications such as acute postpartum hemorrhage.
  • Underestimations of blood loss lead healthcare providers into believing that deployment of postpartum hemorrhage are not necessary, thus, limiting the use of postpartum hemorrhage devices.